Moreover, therapeutic phase II studies with the c-KIT blocker imatinib in unselected melanoma patients without known KIT mutation status were disappointing (Ugurel et al, 2005; Wyman et al, 2006; Becker et al, 2007). This evidence concerns the gene KIT and melanoma.